Ongoing market access barriers for U.S. pharma and medical device companies landed India, Canada and Colombia on the U.S. Trade Representative's annual "Special 301" watch list again. The USTR's annual report reviews global developments on trade and intellectual property, identifying trading partners that USTR, part of the Executive Office of the President, deems to have harmful records on protection, enforcement or market access for U.S. innovators and creators.